Ordinary General Meeting

Welcome!

Nice to meet you!

9 June 2026

Agenda

01 Opening of the Meeting

02 Convocation, Attendance & Voting principles

03 Strategic Update 2025, Financials, Remuneration

04 Questions

05 Resolutions Agenda items - Voting

Convocations, Attendance & Voting

Hyloris®

Opening Meeting

Ordinary General Meeting held on 9 June 2026 at 14:00 (Belgian time) in Liège, Belgium.

The meeting bureau consist of Stefan Yee (Chairman) and Ann De Jaeger (General Secretary).

French is the official language for minutes & resolutions; an English translation of the minutes will be provided.

The Chairman notes that the following directors of the Company participate in the Meeting:
Mr. Stijn Van Rompay, Mr. Thomas Jacobsen, Mr. Vincent Van Dessel and Mr. Stefan Yee.

The Chairman also notes that the statutory auditor of the Company, BDO Réviseurs d'Entreprises, represented by Mr. Christophe Pelzer, participates in this Meeting.

Convocation, Attendance & Voting principles

The meeting was convened in accordance with the Belgian Code of Companies and Associations.

Convening notices were published on 8 May 2026 and supporting documentation was made available on the Company website and ABN Amro Platform.

Shareholders registered on 26 May 2026 are entitled to participate and vote.

Each share entitled to one vote under the articles of association.

Shareholders can vote electronically, by letter, by proxy or attend physically.

The Company’s capital amounts to EUR 140,001.87 and is represented by 28,000,374 shares, without nominal value.

We count Shares represented, corresponding to % of the outstanding share capital.

The Chairman & Meeting confirm that it has been validly convened and is validly constituted.

Strategic Update by CEO 2025 - in Brief

Hyloris®

Forward-Looking Statements

This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, “presentation” means this document, oral presentation, any question and answer session and any written or oral material discussed or distributed during the presentation meetings. This presentation (or any part of it) may not be reproduced or redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (whether inside or outside such person’s organization or firm) or published for any purpose or under any circumstances.

This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any securities of the Company in any jurisdiction and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This presentation does not contain all the information that a prospective purchaser of securities of the Company may desire or require in deciding whether or not to purchase such securities nor does it constitute a due diligence review and should not be construed as such. This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident in any jurisdiction where such distribution or use would be contrary to law or regulation or would require any registration or licensing within such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Any person into whose possession this presentation comes should inform themselves about, and observe, any such restrictions.

This presentation includes market, economic and industry data, which were obtained by the Company from scientific journals, industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers. While the information has been accurately reproduced, and in as far as the Company is aware and is able to ascertain from such third-party information, no facts have been omitted which would render the reproduction of this third-party information inaccurate or misleading, the Company cannot guarantee its accuracy or completeness. Accordingly, you should not place reliance on any of the market, economic and industry data contained in this presentation.

This presentation includes statements that are, or may be deemed to be, “forward-looking statements” which are based on current expectations and projections about future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, these forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. A number of factors could cause actual results or outcomes to differ materially from those expressed, projected or implied in any forward-looking statements. In light of these risks, uncertainties and assumptions, the events or circumstances referred to in the forward-looking statements may not occur. None of the future projections, expectations, estimates or prospects in the materials should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the materials. No one undertakes to publicly update or revise any such forward-looking statement, whether as a result of new information, future events or otherwise. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual results or otherwise.

By attending and otherwise accessing this presentation you will be deemed to have read and understood the contents of this disclaimer. In making an investment decision, you must rely on your own assessment, examination, analysis and enquiry of the Company

Pharma needs faster & more affordable innovation

The traditional way

thousands
of drug candidates are in the pipeline worldwide



only a fraction
make it to market

Slow

Expensive

Risky

Our Mission

We add value
through Reinventing
Existing Medications
for unmet patient needs
worldwide

Reinvent existing &
Invent new medicines

Improve DOSAGE FORM and/or change ROUTE of administration of existing medicines

Target to be MORE EFFECTIVE – MORE PREDICTABLE – MORE CONVENIENT

Repurpose existing medicine for a NEW therapeutic INDICATION (use)

NEW PRODUCT – NEW FIELD
NEW MARKET

New Chemical Entity using own pathway
based on applicable law

REFORMULATING + REPURPOSING

Maximise use (non) clinical data of approved drug product

FDA’s 505(b)(2) pathway (or equivalent) as the engine

- Added value to healthcare system
- Clear scientific & medical rationale
- Approved, well-known molecules
- Defined regulatory pathway
- Addressable market

- Addressing clear unmet needs
- Fast market adoption
- Maximized ROI
- Large potential
- IP protection

*Not adjusted for inflation / exchange rate differences.

Where others stop,

we start and add value.

Reinventing Existing Medicines for Unmet Patient Needs Worldwide

30+
Products in pipeline

3
Commercial products

Innovation Engine

55
Team members

Lowest Financial Loss since IPO / No Financial Debt

Good Governance in Place

Recurring Revenues Improving

Our Product Portfolio (as publicly announced)

3 Strategic Focus Groups for Growth

MAVERICKS

A high-potential product backed with clinical evidence and significant commercial potential:
medium risk – high spent – high success – high value

5

CORE DRIVERS

A catalyst product building a strong recurring revenue base at near term:
low risk – low spent – high success – medium value

15

PROMISING SEEDS

An early-stage product pending clinical validation:
high risk –medium spent – low success - moonshot potential

8

Our Product Portfolio (as publicly announced)

3 Strategic Focus Groups for Growth

Product Fiches will be shared separately

MAVERICKS

- HY-094 (Iron Deficiency Anemia) ★
- Milrinone ER ★
- Miconazole DB
- Suramin IV
- Alenura™ ★

CORE DRIVERS

- Maxigesic® IV
- Sotalol IV
- Podofilox Gel (Generic)
- TXA Oromucosal Solution (XTRAZA®)
- Metolazone IV
- Valacyclovir Oral Suspension
- Atomoxetine Oral Liquid
- Ondansetron ER
- Dofetilide IV ★
- Phosphate Oral Liquid
- Pantoprazole IV RTU ★
- HY-074 (ACS)
- Aspirin IV
- Tranexamic Acid RTU (Generic)
- Fusidic Acid (Generic)

PROMISING SEEDS

- HY-083 (Idiopathic Rhinitis) ★
- HY-095 (Equine Gastric Ulcers) ★
- HY-098 (skin disorder) ★
- HY-089 (BMS) ★
- HY-091 (VLS)
- HY-086 (PTX-252) (AML) ★
- HY-106 Methanobactin (Wilson's) ★
- HY-075

Reformulating
Repurposing
NCE

6 New Products Added in 2025

Hitting our ambitious 30+ portfolio target

6 New Product Candidates Added in 2025

From reformulations to NCEs and NBEs — a landmark year for pipeline expansion

Pantoprazole IV RTU
Reformulation

- Ready-to-use IV formulation — no reconstitution needed
- GERD, erosive esophagitis, Zollinger-Ellison syndrome
- Over 400 million lyophilized vials sold
- Projected development cost below EUR 5 million
- Partnership with Orion (EU/UK/CH/NO) signed Jan 2026

Ondansetron ER
Reformulation

- Once-daily extended-release oral tablet
- Prolonged relief from chemotherapy-induced nausea
- Potential improved adherence vs. immediate-release forms

HY-094 Iron IV
New Chemical Entity (NCE)

- Novel 3rd-gen IV iron deficiency therapy (NCE)
- ~1.3 billion people affected globally by IDA
- Phase 2, 146-patient trial: complications 2.7% vs 29.7% (SOC)
- Phase 3 (~1,000 patients) expected to start in 2026
- Hyloris estimated development cost below EUR 7 million
- Partnership with AFT Pharmaceuticals

Suramin IV
New Chemical Entity (NCE)

- IV formulation for Human African Trypanosomiasis (HAT)
- If approved, qualifies for FDA Tropical Disease PRV
- Hyloris entitled to just over 50% of net PRV sale proceeds
- Hyloris committed up to $3.6M (equity $1.6M + up to $2M R&D)
- Also exploring Autism Spectrum Disorder indication

Methanobactin (ARBM-101)
New Biological Entity (NBE)

- Exclusive EU/Turkey license — targets Wilson's disease
- Rare inherited copper metabolism disorder
- Next-gen copper chelator; exceptional selectivity for Cu ions
- Addresses limitations of current chelation therapies
- Phase 1 (Arbor-101) planned 2026
- Investment of $2M (paid)

HY-098 Topical Skin
Repurposing / Rare Disease

- Rare inherited inflammatory skin disorder
- Recurrent flare-ups, painful lesions, chronic inflammation
- Research collaboration with Wake Forest University
- Novel topical application of well-established active substance
- Potential Orphan Drug Designation; exploratory clinical trial planned

4 Clinical Trial Results in 2025

Delivering data that moves the needle for patients

4 Clinical Trial Results in 2025

Four key readouts — reinforcing our pipeline and supporting regulatory progression

Atomoxetine Oral Liquid

✓ POSITIVE DATA · ADHD — oral liquid formulation

- Clinical data package completed and product submitted to U.S. FDA
- Rosemont Pharmaceuticals signed as U.S. commercial partner
- Liquid formulation improves dosing flexibility for ADHD patients
- Additional clinical work completed for selected international territories

Aspirin IV

✓ POSITIVE PIVOTAL DATA · Acute care — intravenous aspirin

- Positive results from pivotal study achieved in 2025
- IV formulation enables predictable dosing in acute care settings
- Preparation for U.S. FDA submission now underway

Dofetilide IV

✓ PIVOTAL TRIAL COMPLETED · Atrial fibrillation — antiarrhythmic

- Pivotal clinical trial successfully completed in 2025
- Regulatory interaction with FDA MIDD group completed early 2026
- On track toward full U.S. NDA filing — key cardiovascular asset

Alenura™

● INTERIM DATA — POSITIVE RECOMMENDATION · Interstitial Cystitis / Bladder Pain Syndrome

- Alkalinised lidocaine + heparin dual-mode of action; no approved therapy exists
- 4-arm controlled double-blind Phase 2 trial ongoing
- ~100 patients enrolled at interim review, completion expected in 2026
- Independent DMC recommended the study continue as planned

8 Out-Licensing Deals in 2025

Expanding global reach through strategic partnerships

8 Out-Licensing Deals in 2025

Hyloris executed 8 agreements in 2025, covering 5 products across major geographies worldwide

XTRAZA® (TXA Oromucosal)		
Colonis	United Kingdom	*Exclusive license & supply*
Huons	South Korea	*Exclusive license & supply*
AFT Pharmaceuticals	AUS, NZ, CA, ZA	*Exclusive license & supply*
Valacyclovir Oral Liquid		
AFT Pharmaceuticals	AUS, NZ, SG, HK, CA	*Exclusive license & supply*
Qlinic (QliniQ)	Netherlands	*Exclusive commercialization*
HY-094 Iron IV (NCE)		
Grand Life Sciences	China	*Via AFT Pharmaceuticals network*
Tranexamic Acid IV RTU		
Orion Corporation	EU, UK, Norway, Switzerland	*Exclusive license & supply*
Atomoxetine Oral Liquid		
Rosemont Pharmaceuticals	United States	*License & commercialization; NDA submitted Q1 2026*

Early 2026: Continuing the Momentum

Key developments already achieved in the first months of 2026

Orion Partnership — Pantoprazole IV RTU (19 Jan 2026)

- Exclusive license & supply agreement: EU, UK, Switzerland & Norway
- Orion registers, markets and commercializes — hospital-focused rollout
- 50+ million lyophilized vials/yr sold in the target territory
- RTU presentation eliminates reconstitution — streamlines pharmacy & nursing

Atomoxetine Oral Liquid — NDA Filed with U.S. FDA

- NDA submitted to U.S. FDA following completion of clinical data package
- Partner: Rosemont Pharmaceuticals (United States)
- Liquid ADHD formulation improves dosing flexibility and accuracy
- Additional work ongoing for international (ex-U.S.) regulatory submissions

Dofetilide IV — FDA MIDD Regulatory Interaction

- Productive engagement with FDA's Model-Informed Drug Development group
- Supports progression toward full U.S. NDA submission
- Pivotal trial completed 2025 — atrial fibrillation cardiovascular asset

Valacyclovir — OAI at Manufacturing Site & Resolution Pathway

- NDA under FDA review; inspection resulted in OAI at manufacturing site
- No deficiencies identified at Hyloris or commercial partner level
- FDA Complete Response Letter received — manufacturing remediation underway
- Multiple resolution routes being pursued; manufacturer actively remediating

2026 Milestones Ahead

Key clinical, regulatory and commercial milestones expected in 2026

CLINICAL

- Phase 3 starts: HY-094 (Iron IV), Suramin IV
- Phase 1 starts: ARBM-101 (Methanobactin), Pantoprazole IV, PTX-252
- Proof of concept: Miconazole-DB (Bacterial Vaginosis)
- Readouts: Metolazone IV, XTRAZA® Phase 3, Milrinone Phase 1
- Readouts: Alenura Phase 2 full data, HY-074

REGULATORY

- Submissions: Dofetilide IV, Phosphate Oral Liquid
- Submissions: Aspirin IV, Fusidic Acid
- Pending: Valacyclovir Oral Liquid (OAI resolution)
- Pending: Atomoxetine Oral Liquid (NDA filed Q1 2026)
- First Phosphate Oral Liquid approval expected 2027

COMMERCIAL

- TXA RTU: launch with Orion across Europe
- Pantoprazole IV RTU: EU/UK/CH/NO rollout with Orion
- US cardiology positioning: Dofetilide & Metolazone
- Podofilox Gel: stock normalisation and recovery
- New product additions focused on repurposing

HY-094 Ferric for injection

Indication: **Iron Deficiency Anemia (IDA)**

- Innovative NCE injectable iron therapy designed to overcome limitations of current treatments for better convenience and tolerability
- Targeting global intravenous iron drug market forecasted to more than USD 7.41 billion by 2033[1]
- Co-development deal with AFT Pharmaceuticals in March 2025
- Data shows potential reduction in dosing needs, fewer side effects, and lower toxicity vs. standard care
- 146-patient trial demonstrated fewer complications (2.7% vs. 29.7%) and no hypophosphatemia risk
- IND filing with FDA underway; ~1,000-patient global Phase III trial starting soon
- Hyloris' estimated development costs below EUR 7 million

25% of the global population are anemic[2]	Corresponding to ~ 1.9 billion people
66% of the anemic burden due to IDA[2]	Corresponding to ~ 1.3 billion people
Market for intravenous iron drugs[3]	USD 3.2 bn in 2023 growing to >USD 7.4bn in 2033.



1) https://www.biospace.com/intravenous-iron-drugs-market-size-to-worth-around-us-7-41-billion-by-2033
2) In 2021: https://pmc.ncbi.nlm.nih.gov/articles/PMC10465717/
3) https://www.precedenceresearch.com/intravenous-iron-drugs-market

Alenura™

Indication: **Interstitial Cystitis/Bladder Pain Syndrome**

- Defect in inner lining of the bladder = chronic, recurring discomfort & pain
- Alenura 15mL prefilled syringe with a dual mode of action:
  - Alkalinised lidocaine: penetrates bladder wall and provides **immediate pain relief**
  - Heparin: augments bladder mucous, anti-inflammatory and anti-bacterial properties = **prolonged pain relief**
  - **Unique combination**
- 4-arm (controlled double-blind multi-center) clinical trial in the U.S. ongoing, FPFV in June 2023

✓ **Targeting first treatment for acute pain flares**

Patients/year (U.S.)	>6 million
Instillation procedures (U.S.)	3 million

Proven pain reduction in 2 controlled Ph2 trials





HY-083

Indication: **Idiopathic Rhinitis** - chronic rhinitis without a known cause

- Symptoms: Runny nose, stuffy nose, sneezing fits without a medical diagnosis (allergies, infection, inflammation, …)
  - Impacting quality of life daily (sleep patterns, drowsiness, irritability, poor concentration)
  - Molecule with known mechanism of action: blocks TRPV1 receptor in the nose
  - Both rapid and sustainable relief
  - Discovery of TRPV1-receptors was awarded the 2021 Nobel Prize

✓ **Targeting the first reliable treatment**

Market size	7% of population
Absolute numbers	~ 19 million patients in the US ~ 25,8 million patients in Europe
Seeks specialist treatment	13% of the above, following ~8 years of trial and error

No systemic exposure detected in Phase 1 trial

Our Strategy

Potential game changer, geared for growth

Ambition to become the reference in value-added medicines over the coming years

*Not adjusted for inflation/exchange rate differences

**Few Generics

Annual Reports – FY 2025 accounts

Hyloris®

Financial Highlights 2025

(in € thousand)	2025	2024	% change
Non current assets	**13,398**	**11,628**	**+15%**
Intangible assets	5,689	3,838	+48%
Property, Plant and Equipment	225	340	(34%)
Right-of-use assets	1,460	1,652	(12%)
Equity accounted investees	2,543	2,748	(7%)
Other financial assets	1,000	1,000	0%
Trade and other receivables	2,480	2,050	21%
Current assets	**19,959**	**29,708**	**(9%)**
Inventories	52	-	N.A.
Trade and other receivables	5,154	4,859	+6%
Other financial assets	492	556	(12%)
Current tax assets	362	508	(29%)
Prepayment	125	191	(35%)
Cash & cash equivalent	**13,775**	**23,594**	**(42%)**
Total assets	**33,357**	**41,335**	**(19%)**

Statement of financial position

Intangible assets increased mainly following the Methanobactin (ArborMed) acquisition.

Right-of-use assets relate primarily to vehicle leases and office/laboratory facilities.

Trade and other receivables comprise within non-current assets mainly the R&D tax credit and the fair value of a loan and U.S. litigation costs recoverable from API Inc., and within current assets the outstanding trade and income receivables from distribution partners.

Other financial assets comprise the investment in Pleco (non-current) and the remaining Vaneltix loan balance, including accrued interest (current).

Equity-accounted investees decreased slightly from €2.7 million to €2.6 million. The movement reflects a €1.4 million additional investment in Kuvatris (HAT development program) and a €972k reversal of the impairment previously recorded on FHP bv, following the amendment of the Shareholders' Agreement to reflect the BV and aVVC development programs. These positive effects were largely offset by a €2.5 million reduction in the carrying value of the FHP participation, resulting from a decrease in a related financial commitment. The reduction follows a €0.5 million payment made in 2025 and the remaining commitment becoming conditional, leading to a decrease in the corresponding financial liability from €3.0 million at year-end 2024 to nil at year-end 2025.

Cash and cash equivalents amounted to **€13.8 million**, supporting the continued advancement of the Company's development portfolio and providing flexibility to pursue additional strategic growth opportunities.

Financial Highlights 2025

(in € thousand)	2025	2024	% change
Equity	**26,475**	**32,143**	**(18%)**
Share capital	140	140	0%
Share premium	121,513	121,513	0%
Retained earnings	(92,804)	(86,470)	+7%
Other reserves	2,543	2,748	(22%)
Non current liabilities	**1,748**	**2,030**	**(19%)**
Borrowings	1,246	1,490	(16%)
Other financial liabilities	87	68	(19%)
Provisions	416	473	(19%)
Current liabilities	**5,134**	**7,162**	**(28%)**
Borrowings	364	326	+12%
Other financial liabilities	-	3,000	(100%)
Provisions	75	408	(82%)
Trade and other liabilities	(4,695)	(3,428)	+37%
Total Equity & liabilities	**33,357**	**41,335**	**(19%)**

Statement of financial position

Solid **Equity position** of **€26.5 million** thanks to a contained net loss of €6,3 million.

Borrowings mainly comprise IFRS 16 lease liabilities related to vehicles and office/laboratory premises.

Other current financial liabilities decreased to nil, primarily following the amendment of the FHP shareholders' agreement, which reduced the Company's unconditional funding commitment, see previous slide under Equity-accounted investees.

Provisions decreased following the settlement of a fixed legal success fee ($400k) in 2025 and now mainly consist of a $300k contingent legal success fee (fair valued and classified as non-current) and a €300k provision relating to a probable cash outflow to A.forall Group.

Trade and other payables increased mainly due to the USD 2 million payable to ArborMed, which was settled in early January 2026.

Financial Highlights 2025

(in € thousand)	2025	2024	% change
Revenues	7,207	8,458	(15%)
Other operating income	1,626	1,584	+3%
Operating income	**8,832**	**10,043**	**(12%)**
Cost of sales	(379)	(224)	+69%
R&D expenses	(11,281)	(10,265)	+10%
G&A expenses	(4,882)	(5,627)	(13%)
Impairment (or reversal) on equity investees	972	(972)	(200%)
Other operating expenses	(71)	(81)	(12%)
Operating expenses	**(15,641)**	**(17,173)**	**(9%)**
Operating result	**(6,808)**	**(7,130)**	**(5%)**
Net financial result	(101)	787	(113%)
Income taxes	374	-	N.A.
Net result	**(6,334)**	**(6,342)**	**0%**

Operating Income

Operating income amounted to €8,832 thousand in 2025, compared to €10,043 thousand in 2024, primarily reflecting a lower contribution from non-recurring milestone income, partly offset by robust growth in royalty revenues.

Royalty income increased by 15% year-on-year to €5.6 million, despite temporary out-of-stock of Podofilox Gel at year-end. This performance was notably driven by a 98% increase in combined royalties from the other two commercially available products, Maxigesic® IV and Sotalol IV.

Operating Expenses

Research and development expenses increased to €11,281 thousand (2024: €10,265 thousand), mainly due to higher employee-related costs following headcount expansion and continued investment in the development pipeline.

General and administrative expenses decreased to €4,882 thousand (2024: €5,627 thousand), reflecting significantly lower legal and investigation-related costs.

Financial result

Net financial result of 2025 amounted to €-101 thousand, compared with €787 thousand in 2024. The decline mainly reflects lower interest income on cash placements due to reduced interest rates in 2025, and foreign exchange losses on USD financial assets and royalties following the weakening of the USD against the EUR in 2025.

Net result

The Group reported a net loss of €6,334 thousand for the period (2024: €6,342 thousand), remaining broadly stable year-on-year and reflecting continued cost discipline despite sustained investment in R&D and portfolio growth.

Remuneration policy & report (CLO)

Hyloris®

Hyloris®

Executive Committee Remuneration (2025)

Component (€)	Co-CEOs	Other ExCom Members
Annual base salary	384,257	682,150
Short-term variable remuneration	69,022	47,462
Supplementary pension	n.a.	n.a.
Car/transport allowance	n.a.	n.a.
Medical plan	n.a.	n.a.

Board Remuneration (2025)

Name	Remuneration (€)
Stefan Yee	27,500
Leon Van Rompay	17,500
Marc Foidart	11,458
Mélanie Mesdagt	10,208
Revital Rattenbach	25,417
Vincent Van Dessel	25,417

Updated Remuneration Policy – Key Amendments

Submitted for AGM approval (binding shareholder vote).
Changes agreed in principle by the RNC on 18 March 2026.

1) LTI Framework: Formal inclusion of LTI - warrant/ESOP mechanism within executive remuneration (and for key employees).

2) Chairman Fee: Reflects €5,000 increase effective upon appointment of new chairman (9 June 2026).

3) PSC confirmed - participation of independent external experts in line with governance practice.

4) Administrative Updates: Registered office, governance references and Charter alignment updates.

Q&A

Hyloris®


LEGIAPARK
CHC MontLégia
LégiaPark
Consultation
CHC SAG/Crèche
ORIGINES
ORIGINES

Agenda Items – Resolutions

Hyloris®

Resolutions – Agenda Items

1. Take cognizance of the Board of Directors' annual report for the financial year ending on the 31st of December 2025.
2. Take cognizance of the statutory auditor's audit report for the financial year ending on the 31st of December 2025.
3. **Approve the non-consolidated annual accounts for the financial year ending on the 31st of December 2025 and approve the profit-and-loss allocation set out therein.**
4. Take cognizance of the Board of Directors' and the statutory auditor's reports on the consolidated annual accounts for the financial year ending on the 31st of December 2025.
5. Take cognizance of the consolidated annual accounts for the financial year ending on the 31st of December 2025.
6. **Grant discharge to the directors.**
7. **Grant discharge to the statutory auditor.**
8. **Vote (advisory vote) on the remuneration report** for the financial year ending on the 31st of December 2025.
9. **Approve the amended remuneration policy 2026-2029**
10. Powers.

Questions

Shareholders were invited to ask questions on agenda items: no questions received prior to the meeting.
No additional agenda requests were submitted before the meeting.
Minutes will be published online after meeting.

Hyloris®

Agenda Item 1

Take cognizance of the Board of Directors' annual report for the financial year ending on the 31st of December 2025.

Prendre connaissance du rapport annuel du Conseil d'Administration relatif à l'exercice clos le 31 décembre 2025.

***Proposed Resolution**: This agenda item does not require a resolution. The Meeting takes note of the Board of Directors' report for FY2025.*

Agenda Item 2

Take cognizance of the statutory auditor’s audit report for the financial year ending on the 31st of December 2025.

Prendre connaissance du rapport annuel du commissaire relatif à l’exercice clos le 31 décembre 2025.

***Proposed Resolution**: This agenda item does not require a resolution. The Meeting takes note of the statutory auditor’s report for FY2025.*

Agenda Item 3

Approve the non-consolidated annual accounts for the financial year ending on the 31st of December 2025 and approve the profit-and-loss allocation set out therein.

Approuver les comptes annuels statutaires de l'exercice clos le 31 décembre 2025 et l'affectation du résultat qui y est reprise.

***Proposed Resolution**: Proposed to approve the non-consolidated annual accounts for FY2025 and the profit-and-loss allocation proposed by the Board of Directors.*

L'affectation du résultat est la suivante :

Perte de l'exercice de 2025	**1.205.801 EUR**
Perte reportée de l'exercice précédent	33.297.781 EUR
Perte à reporter	34.503.582 EUR

Voting Result

FOR	AGAINST	ABSTAIN
[•]	[•]	[•]

Agenda Item 4

Take cognizance of the Board of Directors' and the statutory auditor's reports on the consolidated annual accounts for the financial year ending on the 31st of December 2025.

Prendre connaissance des rapports du Conseil d'Administration et du commissaire portant sur les comptes annuels consolidés de l'exercice clos le 31 décembre 2025.

***Proposed Resolution**: This agenda item does not require a resolution. The Meeting takes note of the Board of Directors' and statutory auditor's reports on the consolidated annual accounts for FY2025.*

Agenda Item 5

Take cognizance of the consolidated annual accounts for the financial year ending on the 31st of December 2025.

Prendre connaissance des comptes annuels consolidés de l'exercice clos le 31 décembre 2025.

***Proposed Resolution**: This agenda item does not require a resolution. The Meeting takes note of the consolidated annual accounts for FY2025.*

Agenda Item 6

Grant discharge to the directors.

Donner décharge aux administrateurs.

***Proposed Resolution**: Proposed to grant discharge to each director for the performance of duties during FY2025.*

Voting Result

FOR	AGAINST	ABSTAIN
[●]	[●]	[●]

Agenda Item 7

Grant discharge to the statutory auditor.

Donner décharge au commissaire.

***Proposed Resolution**: Proposed to grant discharge to the statutory auditor, BDO Réviseurs d'Entreprises SRL, represented by Mr. Christophe Pelzer, for FY2025.*

Voting Result

FOR	AGAINST	ABSTAIN
[●]	[●]	[●]

Agenda Item 8

Vote (advisory vote) on the remuneration report for the financial year ending on the 31st of December 2025.

Voter (vote consultatif) sur le rapport de rémunération pour l'exercice clos le 31 décembre 2025.

***Proposed Resolution**: Proposed to approve the remuneration report for FY2025 as included in the annual report.*

Voting Result

FOR	AGAINST	ABSTAIN
[●]	[●]	[●]

Agenda Item 9

Approve the amended remuneration policy 2026-2029.

Approuver la politique de rémunération 2026 - 2029 modifiée.

***Proposed Resolution**: Proposed to approve the amended remuneration policy 2026–2029.*

Voting Result

FOR	AGAINST	ABSTAIN
[●]	[●]	[●]

Agenda Item 10

Grant power of attorney for the performance of formalities.

Donner procuration pour l'accomplissement des formalités.

Proposed Resolution: *This agenda item does not require a resolution.*
The Meeting takes note of the Board of Directors' report for FY2025.

Value Starts Here

Hyloris Pharmaceuticals SA - 2026

HQ: Boulevard Patience Et Beaujonc N°3/1
4000 Liège, Belgium

+32(0)4 346 02 07

contact@hyloris.com
investorrelations@hyloris.com